CPRX
Price
$25.89
Change
+$0.54 (+2.13%)
Updated
Jun 6, 04:13 PM (EDT)
Capitalization
3.09B
61 days until earnings call
FOLD
Price
$6.18
Change
+$0.22 (+3.69%)
Updated
Jun 6, 04:20 PM (EDT)
Capitalization
1.84B
55 days until earnings call
Interact to see
Advertisement

CPRX vs FOLD

Header iconCPRX vs FOLD Comparison
Open Charts CPRX vs FOLDBanner chart's image
Catalyst Pharmaceuticals
Price$25.89
Change+$0.54 (+2.13%)
Volume$700
Capitalization3.09B
Amicus Therapeutics
Price$6.18
Change+$0.22 (+3.69%)
Volume$44.06K
Capitalization1.84B
CPRX vs FOLD Comparison Chart
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPRX vs. FOLD commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Buy and FOLD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CPRX: $25.36 vs. FOLD: $5.96)
Brand notoriety: CPRX and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 84% vs. FOLD: 78%
Market capitalization -- CPRX: $3.09B vs. FOLD: $1.84B
CPRX [@Biotechnology] is valued at $3.09B. FOLD’s [@Biotechnology] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 2 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • CPRX’s FA Score: 2 green, 3 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, CPRX is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • CPRX’s TA Score: 5 bullish, 2 bearish.
  • FOLD’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than FOLD.

Price Growth

CPRX (@Biotechnology) experienced а +3.17% price change this week, while FOLD (@Biotechnology) price change was -4.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.54%. For the same industry, the average monthly price growth was +17.23%, and the average quarterly price growth was +3.31%.

Reported Earning Dates

CPRX is expected to report earnings on Aug 06, 2025.

FOLD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($3.09B) has a higher market cap than FOLD($1.84B). CPRX YTD gains are higher at: 21.514 vs. FOLD (-36.730). CPRX has higher annual earnings (EBITDA): 269M vs. FOLD (53.6M). CPRX has more cash in the bank: 581M vs. FOLD (251M). CPRX has less debt than FOLD: CPRX (3.09M) vs FOLD (443M). FOLD (543M) and CPRX (535M) have equivalent revenues.
CPRXFOLDCPRX / FOLD
Capitalization3.09B1.84B169%
EBITDA269M53.6M502%
Gain YTD21.514-36.730-59%
P/E Ratio16.15N/A-
Revenue535M543M99%
Total Cash581M251M231%
Total Debt3.09M443M1%
FUNDAMENTALS RATINGS
CPRX vs FOLD: Fundamental Ratings
CPRX
FOLD
OUTLOOK RATING
1..100
1655
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
16100
SMR RATING
1..100
3392
PRICE GROWTH RATING
1..100
4288
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (61) in the Pharmaceuticals Other industry is in the same range as FOLD (64) in the Biotechnology industry. This means that CPRX’s stock grew similarly to FOLD’s over the last 12 months.

CPRX's Profit vs Risk Rating (16) in the Pharmaceuticals Other industry is significantly better than the same rating for FOLD (100) in the Biotechnology industry. This means that CPRX’s stock grew significantly faster than FOLD’s over the last 12 months.

CPRX's SMR Rating (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for FOLD (92) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than FOLD’s over the last 12 months.

CPRX's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for FOLD (88) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than FOLD’s over the last 12 months.

CPRX's P/E Growth Rating (92) in the Pharmaceuticals Other industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CPRX’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXFOLD
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 4 days ago
69%
Declines
ODDS (%)
Bearish Trend 16 days ago
69%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEGFX60.32N/A
N/A
American Funds EUPAC F1
FLDGX13.95N/A
N/A
Meeder Dynamic Allocation Retail
LVORX16.64N/A
N/A
Lord Abbett Value Opportunities R3
DPRCX12.64N/A
N/A
Macquarie Global Listed Real Assets C
THGCX25.41-0.04
-0.16%
Thornburg International Equity C

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
+0.28%
VIR - CPRX
45%
Loosely correlated
-2.37%
CRNX - CPRX
44%
Loosely correlated
+0.59%
SANA - CPRX
44%
Loosely correlated
+9.70%
LGND - CPRX
42%
Loosely correlated
+0.27%
FOLD - CPRX
40%
Loosely correlated
-2.30%
More

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-2.30%
VCYT - FOLD
43%
Loosely correlated
-1.17%
ROIV - FOLD
42%
Loosely correlated
-0.18%
RARE - FOLD
41%
Loosely correlated
+0.76%
ATXS - FOLD
41%
Loosely correlated
-1.14%
KRYS - FOLD
41%
Loosely correlated
+0.53%
More